In yesterday’s Wall Street session, Blueprint Medicines Corp (NASDAQ:BPMC) shares traded at $67.01, up 1.07% from the previous session.
As of this writing, 19 analysts cover Blueprint Medicines Corp (NASDAQ:BPMC). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $114.00 and a low of $50.00, we find $85.00. Given the previous closing price of $66.30, this indicates a potential upside of 28.21 percent. BPMC stock price is now 25.70% away from the 50-day moving average and 28.71% away from the 200-day moving average. The market capitalization of the company currently stands at $4.07B.
There are 3 analysts who have given it a hold rating, whereas 13 have given it a buy rating. Brokers who have rated the stock have averaged $79.50 as their price target over the next twelve months.
With the price target maintained at $85, Oppenheimer recently Upgraded its rating from Perform to Outperform for Blueprint Medicines Corp (NASDAQ: BPMC).
In other news, Albers Jeffrey W., Director sold 1,485 shares of the company’s stock on Nov 03. The stock was sold for $89,293 at an average price of $60.13. Upon completion of the transaction, the Director now directly owns 176,050 shares in the company, valued at $11.8 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 02, Director Albers Jeffrey W. sold 4,634 shares of the business’s stock. A total of $279,749 was realized by selling the stock at an average price of $60.37. This leaves the insider owning 176,050 shares of the company worth $11.8 million. Insiders disposed of 115,959 shares of company stock worth roughly $7.77 million over the past 1 year. A total of 2.07% of the company’s stock is owned by insiders.
Wednesday morning saw Blueprint Medicines Corp (NASDAQ: BPMC) opened at $67.00. During the past 12 months, Blueprint Medicines Corp has had a low of $37.82 and a high of $68.00. As of last week, the company has a debt-to-equity ratio of 3.82, a current ratio of 4.09, and a quick ratio of 4.01. The fifty day moving average price for BPMC is $53.31 and a two-hundred day moving average price translates $52.06 for the stock.
The latest earnings results from Blueprint Medicines Corp (NASDAQ: BPMC) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$2.2, beating analysts’ expectations of -$2.37 by 0.17. This compares to -$2.23 EPS in the same period last year. The net profit margin was -256.57% and return on equity was -131.62% for BPMC. The company reported revenue of $56.57 million for the quarter, compared to $65.98 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -14.26 percent. For the current quarter, analysts expect BPMC to generate $66.81M in revenue.
Blueprint Medicines Corp(BPMC) Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
